Related Experiment Video
Updated: Jun 21, 2025
Isolation of Pulmonary Artery Smooth Muscle Cells from Neonatal Mice
Published on: October 19, 2013
Effects of PGE1 on the ERS pathway in neonatal rats with hyperoxic lung injury
Zhenlin Yang1, Jianing Song2, Jingjing Guo1
1Department of Pediatrics, Yanbian University Hospital, Yanji, 133000, China.
Insights
Prostaglandin E1 (PGE1) effectively treats hyperoxic lung injury in newborn rats by reducing inflammation and apoptosis. This finding offers a potential new treatment for bronchopulmonary dysplasia (BPD).
Area of Science:
- Neonatal physiology
- Pulmonary medicine
- Pharmacology
Background:
- Oxygen therapy is crucial for low birth weight infants but can cause hyperoxic lung injury and bronchopulmonary dysplasia (BPD).
- Prostaglandin E1 (PGE1) is known for its anti-inflammatory and circulatory benefits.
- Investigating PGE1's therapeutic potential for hyperoxic lung injury is warranted.
Purpose of the Study:
- To evaluate the therapeutic effects of Prostaglandin E1 (PGE1) on hyperoxic lung injury in neonatal rats.
- To elucidate the underlying mechanisms of PGE1's action in mitigating lung injury.
Main Methods:
- A hyperoxic lung injury model was established in newborn rats.
- Intraperitoneal injection of PGE1 was administered to assess its interventional effects.
- Techniques included Diff-Quick staining, lung wet/dry weight ratio, HE staining, TUNEL assay, ELISA, and Western blot analysis.
Main Results:
- PGE1 treatment significantly reduced inflammatory and apoptotic cells compared to the control group (p < 0.05).
- Levels of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) were significantly decreased in the PGE1-treated group (p < 0.05).
- Expression of apoptosis-related proteins (Caspase-3, CHOP, GRP78) and the Bcl-2/Bax ratio were significantly altered by PGE1 treatment (p < 0.05).
Conclusions:
- PGE1 demonstrates a significant therapeutic effect on hyperoxic lung injury in neonatal rats.
- PGE1 treatment mitigates inflammation and apoptosis, potentially via the endoplasmic reticulum stress pathway.
- These findings suggest PGE1 as a promising therapeutic agent for bronchopulmonary dysplasia (BPD).
Background:
With the increase in the number of low birth weight infants, oxygen therapy is more widely used. However, chronic high-concentration oxygen environments lead to hyperoxic lung injury in children, which in turn leads to bronchopulmonary dysplasia (BPD). PGE1 is widely used in the clinic for its ability to inhibit inflammation and improve circulation. Therefore, we further investigated whether PGE-1 has a therapeutic effect on hyperoxic lung injury.
Methods:
Hyperoxic lung injury model was adopted for investigating the interventional effects and underlying mechanisms of intraperitoneal injection of prostaglandin E1 (PGE-1) on hyperoxic lung injury in newborn rats via relevant experimental techniques, such as Diff-Quick staining, lung wet dry specific gravity measurements, HE staining, TUNEL staining, ELISA, and the Western blot method.
Results:
Inflammatory and apoptotic cells in the PGE1-treated group were significantly lower than those in the hyperoxic lung injury group (p < 0.05); and the contents of IL-1β, IL-6 and TNF-α in the treated group were significantly lower than those in the model group (p < 0.05). Caspase-3, CHOP, GRP78 and Bcl-2/Bax protein expression in the treatment group was significantly lower than that in the model group (p < 0.05).
Conclusion:
PGE-1 has a therapeutic effect on hyperoxic lung injury in neonatal rats.
Impact:
PGE1 treatment reduces levels of inflammatory cells and pro-inflammatory cytokines and decreases apoptosis. PGE1 has a therapeutic effect on BPD through the endoplasmic reticulum stress pathway. This study offers the possibility of PGE1 for the treatment of BPD.
